Actinogen requested the halt pending details regarding Actinogen Medical’s application to the FDA to initiate its XanADu Phase II clinical trial in the US of Xanamem in the treatment of Alzheimer’s disease.
The halt will remain in place until the opening of trade on Wednesday 4th January 2017, or earlier if an announcement is made to the market.